Procter & Gamble Hygiene & Health Care Ltd. (PGHH) AI Stock Analysis

• Market Cap: ₹435.30B
• Dividend Yield: 2.05%
• Average Volume (3M): 854.00
• Price to Earnings (P/E): 52.5
• Beta (1Y): 0.36
• Revenue Growth: 8.28%
• EPS Growth: 11.65%
• Country: IN
• Employees: 439
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 64.65
• Shares Outstanding: 32,460,735
• 10 Day Avg. Volume: 1,521
• 30 Day Avg. Volume: 854
• PEG Ratio: 2.02
• Price to Book (P/B): 59.85
• Price to Sales (P/S): 9.80
• P/FCF Ratio: 78.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ₹14,470.00 ▲(10.07% Upside)

Procter & Gamble Hygiene & Health Care Ltd. demonstrates strong financial performance with consistent growth and profitability, which is the most significant factor in its overall score. The technical analysis indicates a bearish trend, and the valuation suggests the stock may be overvalued, slightly offsetting the strong financials. The absence of earnings call data and corporate events means these factors do not influence the score.

Procter & Gamble Hygiene & Health Care Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Hygiene & Health Care Ltd. (PGHH) is a subsidiary of the global consumer goods giant Procter & Gamble, specializing in hygiene and health care products. The company operates primarily in the fast-moving consumer goods (FMCG) sector, offering a range of products including personal care items, health supplements, and hygiene essentials. PGHH is known for its commitment to innovation and quality, serving a diverse customer base and enhancing everyday life with trusted brands.

How the Company Makes Money

PGHH generates revenue through the sale of its wide array of hygiene and health care products, which are distributed through various channels including retail stores, e-commerce platforms, and direct sales. The company employs a business model centered around brand loyalty and market penetration, benefiting from established brand recognition and customer trust in its products. Key revenue streams include sales of personal care products like shampoos and skin care items, as well as health care products such as over-the-counter medicines and dietary supplements. Additionally, PGHH may engage in strategic partnerships with retailers and distributors to enhance product availability and visibility, contributing to its overall sales performance.

Procter & Gamble Hygiene & Health Care Ltd. Financial Statement Overview

Summary

Procter & Gamble Hygiene & Health Care Ltd. exhibits a strong financial position across all verticals. The income statement reflects consistent growth and profitability, the balance sheet indicates financial stability with low leverage, and the cash flow statement shows strong cash generation capabilities. The company is well-positioned to sustain its growth trajectory and manage potential risks effectively.

Income Statement

Procter & Gamble Hygiene & Health Care Ltd. demonstrates strong financial performance with consistent revenue growth and healthy profit margins. The gross profit margin remains robust, indicating efficient cost management, while the net profit margin shows solid profitability. The EBIT and EBITDA margins are stable, reflecting effective operational management. Overall, the income statement reflects a positive growth trajectory and profitability.

Balance Sheet

The company's balance sheet is characterized by a very low debt-to-equity ratio, indicating minimal leverage and financial stability. The return on equity is strong, showcasing effective utilization of shareholder funds to generate profits. The equity ratio is healthy, suggesting a solid capital structure. However, a slight decrease in stockholders' equity over the years could be a point of concern.

Cash Flow

The cash flow statement reveals a positive trend in free cash flow growth, indicating strong cash generation capabilities. The operating cash flow to net income ratio is healthy, suggesting efficient conversion of income into cash. The free cash flow to net income ratio is also strong, reflecting the company's ability to generate cash relative to its net income. Overall, the cash flow position is robust, supporting the company's operational and strategic initiatives.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	43.02B	44.99B	42.06B	39.05B	39.01B	35.70B
Gross Profit	25.84B	25.48B	25.76B	22.42B	17.17B	22.42B
EBITDA	12.11B	12.11B	10.22B	8.98B	8.43B	9.18B
Net Income	7.18B	8.49B	6.75B	6.78B	5.76B	6.52B
Balance Sheet
Total Assets	17.55B	17.55B	18.59B	21.37B	16.81B	16.33B
Cash, Cash Equivalents and Short-Term Investments	5.16B	5.16B	5.74B	9.64B	6.25B	6.48B
Total Debt	23.20M	23.20M	30.80M	40.30M	51.00M	34.70M
Total Liabilities	10.18B	10.18B	10.84B	11.91B	9.44B	9.18B
Stockholders Equity	7.37B	7.37B	7.75B	9.46B	7.38B	7.14B
Cash Flow
Free Cash Flow	5.15B	5.63B	4.26B	7.81B	5.23B	8.32B
Operating Cash Flow	5.73B	6.18B	4.71B	8.26B	5.73B	8.63B
Investing Cash Flow	-525.30M	-586.30M	10.60M	-99.10M	-268.50M	69.40M
Financing Cash Flow	-12.19B	-6.66B	-8.62B	-4.77B	-5.69B	-11.06B

Procter & Gamble Hygiene & Health Care Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13146.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHH, the sentiment is Negative. The current price of 13146.55 is below the 20-day moving average (MA) of 13706.70, below the 50-day MA of 13634.65, and below the 200-day MA of 13643.90, indicating a bearish trend. The MACD of -150.98 indicates Positive momentum. The RSI at 32.65 is Neutral, neither overbought nor oversold. The STOCH value of 20.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PGHH.

Procter & Gamble Hygiene & Health Care Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZYDUSWELL	73 Outperform	₹143.17B	56.50	―	0.27%	14.55%	-20.61%
COLPAL	70 Outperform	₹595.77B	44.93	―	2.35%	-2.06%	-9.74%
DABUR	66 Neutral	₹917.00B	50.67	―	1.54%	2.68%	1.07%
EMAMILTD	64 Neutral	₹236.01B	28.68	―	1.55%	4.06%	10.78%
PGHH	63 Neutral	₹435.30B	52.53	―	2.05%	8.28%	11.65%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
GILLETTE	56 Neutral	₹283.63B	49.41	―	1.32%	7.42%	22.99%

Procter & Gamble Hygiene & Health Care Ltd. Corporate Events

Procter & Gamble Hygiene and Health Care Holds 61st AGM Virtually

Procter & Gamble Hygiene and Health Care Limited held its 61st Annual General Meeting on September 4, 2025, via video conferencing. The meeting was chaired by Mr. Gurcharan Das, due to the absence of the usual chairperson, Mr. Chittranjan Dua. The AGM was conducted in compliance with guidelines from the Ministry of Corporate Affairs and SEBI, with key board members and management representatives present. The meeting facilitated the discussion of the company’s annual report and other statutory matters, reflecting the company’s adherence to regulatory requirements and its commitment to transparent communication with shareholders.

P&G Hygiene and Health Care Re-Submits Q2 Financial Results

Procter & Gamble Hygiene and Health Care Limited has re-submitted its unaudited financial results for the quarter ending June 30, 2025, due to the previous submission not being in a machine-readable format as required by the exchange. This update ensures compliance with exchange requirements and maintains transparency with stakeholders regarding the company’s financial performance.

Procter & Gamble Approves Q2 2025 Financial Results

Procter & Gamble Hygiene and Health Care Limited announced the approval of its unaudited financial results for the quarter ending June 30, 2025, during a board meeting. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and operational health, potentially impacting its market positioning and investor confidence.

Procter & Gamble Re-appoints Independent Director for Five-Year Term

Procter & Gamble Hygiene and Health Care Limited has announced the re-appointment of Mr. Chittranjan Dua as an Independent Director for a five-year term starting August 25, 2025. This decision, approved by the Board of Directors and subject to shareholder approval, underscores the company’s commitment to maintaining experienced leadership. Mr. Dua meets all regulatory criteria for independence and is not disqualified from holding the director position, ensuring compliance with corporate governance standards.